HLA-G or HLA-E could be valuable enhancers of immune responses in other cancers and for NK-cell targeted strategies, as shown for the anti-NKG2A blocking antibody monalizumab now developed as a novel first-in-class checkpoint inhibitor for HLA-E-positive cancers [18]. The gene discussed is HLA-E; the disease is cancer.